Nanopublication: RA8UPrR6-P

Full identifier: http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RA8UPrR6-P comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:24:17.881+02:00" .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 13:24:17 UTC

show references